CHF Solutions Ships Aquadex SmartFlow Products to Florida for Use with COVID-19 Patients
June 11 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced that it has sold Aquadex SmartFlow™ consoles and
disposables to a critical care hospital for use in the treatment of
COVID-19 patients in Central Florida.
Managing fluid balance in critically ill COVID-19 patients is
important to avoid potentially life-threatening complications, such
as volume overload, acute respiratory distress syndrome (ARDS), and
other conditions related to progressive congestion. Because of this
need, several hospitals across the country have included a
simplified ultrafiltration system, such as Aquadex therapy, into
their treatment protocol for fluid management for COVID-19
patients, especially when dialysis equipment and staff are limited.
As recently cited, isolated ultrafiltration is an optimal strategy
that primarily focuses on fluid extraction and optimization of
volume status.1 The Aquadex SmartFlow system, a portable
ultrafiltration device with small extracorporeal volume (i.e. 35
ml), provides a predictable method for fluid extraction, making it
more likely to achieve precise fluid balance in these
patients.
“Hospitals continue to see the need for ultrafiltration to treat
patients affected with COVID-19 throughout the country,” said John
Erb, CEO of CHF Solutions. “The Aquadex SmartFlow system provides a
simple, predictable and smart solution and we are pleased that the
therapy is being used to help patients in Central Florida.”
1 https://pubmed.ncbi.nlm.nih.gov/32336959/
About CHF Solutions CHF Solutions, Inc. (CHFS)
is a medical device company dedicated to changing the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing and commercializing the Aquadex SmartFlow
system for ultrafiltration therapy. CHF Solutions is headquartered
in Minneapolis, Minn., with wholly-owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex
SmartFlow system is indicated for temporary (up to 8 hours) or
extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the use of
the Aquadex system to treat patients affected with COVID-19.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024